C
Cancilico develops AI-powered software, including MyeloAID, for image-based diagnostics focused on hematological cancers. This technology automates the classification and counting of cells in bone marrow smears to provide rapid, accurate analysis. The company offers tailored AI services to enhance precision and efficiency in medical research and clinical workflows.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Cancilico develops AI-powered software, including MyeloAID, for image-based diagnostics focused on hematological cancers. This technology automates the classification and counting of cells in bone marrow smears to provide rapid, accurate analysis. The company offers tailored AI services to enhance precision and efficiency in medical research and clinical workflows.